MA32419B1 - Materiaux et procedes permettant de supprimer et/ou de traiter un neurofibrome et des tumeurs associees - Google Patents

Materiaux et procedes permettant de supprimer et/ou de traiter un neurofibrome et des tumeurs associees

Info

Publication number
MA32419B1
MA32419B1 MA33461A MA33461A MA32419B1 MA 32419 B1 MA32419 B1 MA 32419B1 MA 33461 A MA33461 A MA 33461A MA 33461 A MA33461 A MA 33461A MA 32419 B1 MA32419 B1 MA 32419B1
Authority
MA
Morocco
Prior art keywords
neurofibroma
cells
plexiform
nfi
tumor
Prior art date
Application number
MA33461A
Other languages
Arabic (ar)
English (en)
Inventor
D Wade Clapp
David Ingram
feng-chun Yang
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41445287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32419(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of MA32419B1 publication Critical patent/MA32419B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des mutations d'une lignée germinale dans le gène suppresseur de tumeur nfi dans la neurofibromatose de type 1 de von recklinghausen (nfi), un trouble génétique courant du système nerveux qui se caractérise par le développement d'un neurofibrome plexiforme. L'utilisation du transfert adoptif de cellules hématopoïétiques, a permis que le caractère hétérozygosité de nfi des cellules provenant de la moelle osseuse dans le microenvironnement tumoral était suffisant pour permettre la progression du neurofibrome dans le contexte de la zygosité inexistante des cellules de schwann. De plus, l'atténuation génétique ou pharmacologique de la voie de signalisation du kit-c dans les cellules hématopoïétiques réduit considérablement le démarrage et la progression du neurofibrome. Ces études ont permis d'identifier les cellules hématopoïétiques haploinsuffisantes et le récepteur du kit-c en tant que cibles thérapeutiques pour prévenir des neurofibromes plexiformes et impliquer des mastocytes en tant que médiateurs critiques du déclenchement de la tumeur. L'administration de doses thérapeutiquement efficaces d'un inhibiteur de tyrosine kinase, tel que le composé imatinib mésylate à un patient qui le nécessite permet de traiter des tumeurs chez un patient humain présentant un neurofibrome plexiforme.
MA33461A 2008-06-27 2010-12-27 Materiaux et procedes permettant de supprimer et/ou de traiter un neurofibrome et des tumeurs associees MA32419B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7618508P 2008-06-27 2008-06-27
US10365008P 2008-10-08 2008-10-08
PCT/US2009/048554 WO2009158447A2 (fr) 2008-06-27 2009-06-25 Matériaux et procédés permettant de supprimer et/ou de traiter un neurofibrome et des tumeurs associées

Publications (1)

Publication Number Publication Date
MA32419B1 true MA32419B1 (fr) 2011-06-01

Family

ID=41445287

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33461A MA32419B1 (fr) 2008-06-27 2010-12-27 Materiaux et procedes permettant de supprimer et/ou de traiter un neurofibrome et des tumeurs associees

Country Status (18)

Country Link
US (3) US20110195975A1 (fr)
EP (1) EP2291186A4 (fr)
JP (2) JP2011526292A (fr)
KR (2) KR20160011713A (fr)
CN (2) CN102099038A (fr)
AU (1) AU2009262214B9 (fr)
BR (1) BRPI0914618A2 (fr)
CA (1) CA2727737C (fr)
CL (1) CL2009001486A1 (fr)
EA (2) EA201500525A1 (fr)
IL (1) IL209973A (fr)
MA (1) MA32419B1 (fr)
MX (1) MX2010013918A (fr)
NZ (1) NZ590076A (fr)
SG (1) SG192444A1 (fr)
TW (1) TWI508728B (fr)
WO (1) WO2009158447A2 (fr)
ZA (1) ZA201009066B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3381943T3 (da) 2012-07-25 2022-05-16 Celldex Therapeutics Inc Anti-kit-antistoffer og anvendelser deraf
JP6768639B2 (ja) * 2014-05-23 2020-10-21 セルデックス セラピューティクス，インコーポレーテッド 好酸球又はマスト細胞関連障害の治療
KR101894769B1 (ko) 2017-12-05 2018-09-04 아주대학교산학협력단 siRNA를 포함하는 신경섬유육종 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
CA2439440A1 (fr) * 2002-09-05 2004-03-05 Emory University Traitement de tumeurs associees a la sclerose tubereuse
CA2629132C (fr) * 2005-12-06 2014-05-27 Novartis Ag Derives de pyrimidylaminobenzamide pour le traitement d'une neurofibromatose
WO2009100176A2 (fr) * 2008-02-07 2009-08-13 Abbott Laboratories Forme pharmaceutique pour administration orale d’un inhibiteur de tyrosine kinase

Also Published As

Publication number Publication date
KR20110044945A (ko) 2011-05-03
IL209973A (en) 2015-11-30
AU2009262214A1 (en) 2009-12-30
TWI508728B (zh) 2015-11-21
EA201500525A1 (ru) 2015-11-30
JP2015187104A (ja) 2015-10-29
EA201071340A1 (ru) 2011-12-30
JP2011526292A (ja) 2011-10-06
WO2009158447A2 (fr) 2009-12-30
US9345704B2 (en) 2016-05-24
SG192444A1 (en) 2013-08-30
US20150072992A1 (en) 2015-03-12
NZ590076A (en) 2012-11-30
US20140121214A1 (en) 2014-05-01
US20110195975A1 (en) 2011-08-11
CL2009001486A1 (es) 2010-04-16
IL209973A0 (en) 2011-02-28
EA022611B1 (ru) 2016-02-29
AU2009262214B2 (en) 2014-12-11
EP2291186A4 (fr) 2011-06-22
KR20160011713A (ko) 2016-02-01
CN105726542A (zh) 2016-07-06
CA2727737A1 (fr) 2009-12-30
ZA201009066B (en) 2011-08-31
TW201006472A (en) 2010-02-16
CA2727737C (fr) 2016-08-23
EP2291186A2 (fr) 2011-03-09
AU2009262214B9 (en) 2015-04-30
US8933082B2 (en) 2015-01-13
CN102099038A (zh) 2011-06-15
BRPI0914618A2 (pt) 2017-06-06
WO2009158447A9 (fr) 2010-03-25
MX2010013918A (es) 2011-07-04

Similar Documents

Publication Publication Date Title
Zou et al. Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer
Tysnes et al. Cancer initiation and progression: involvement of stem cells and the microenvironment
Ubhi et al. Exploiting DNA replication stress for cancer treatment
Van Maerken et al. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma
Schmid et al. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases
Kirches et al. High frequency of mitochondrial DNA mutations in glioblastoma multiforme identified by direct sequence comparison to blood samples
Durinck et al. Epigenetic regulation of neuroblastoma development
MA48772B1 (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
Padul et al. ETV/Pea3 family transcription factor‐encoding genes are overexpressed in CIC‐mutant oligodendrogliomas
Asselin-Labat et al. Adult lung stem cells and their contribution to lung tumourigenesis
Marschalek MLL leukemia and future treatment strategies
Gilbert-Ross et al. Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma
DK1766077T3 (da) Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse
MA30084B1 (fr) Triazolopyridazines en tant que modulateurs de la tyrosine kinase
Kaur et al. Bromodomain and hedgehog pathway targets in small cell lung cancer
MA31001B1 (fr) Quinazolines destines a l'inhibition de pdk
MA33606B1 (fr) Dérivés de pyrimidine en tant qu'inhibiteurs de protéine tyrosine kinase 2
Wu et al. EGFR amplification induces increased DNA damage response and renders selective sensitivity to talazoparib (PARP inhibitor) in glioblastoma
MA32419B1 (fr) Materiaux et procedes permettant de supprimer et/ou de traiter un neurofibrome et des tumeurs associees
MA33658B1 (fr) N-4(-((3-(2-amino-4 pyrimidinyl)-2-pyridinyl)oxy)phényl)-4-(4-méthyl-2- thiényl)-1-phtalazinamine destinée à être utilisée dans le traitement d'un cancer résistant aux agents antimitotiques
Alekseeva et al. Alteration of the exDNA profile in blood serum of LLC-bearing mice under the decrease of tumour invasion potential by bovine pancreatic DNase I treatment
MA50675B1 (fr) Inhibiteurs de la creb binding protein (cbp)
WO2007120847A3 (fr) Identification et modulation de voies moléculaires qui induisent la plasticité du système nerveux
Mutvei et al. Frequency and distribution of Notch mutations in tumor cell lines
Hide et al. Brain tumor stem cells as research and treatment targets